20122 ⎘
Medicinal preparations characterised by special physical form; Pills, tablets, discs, rods; Dragees; Coated pills or tablets, e.g. with film or compression coating; Coating materials Organic compounds, e.g. fats
Modified release compositions of epalrestat or a derivative thereof and methods for using the same
#302Controlled release hydrocodone formulations
#303ORGANIC COMPOUNDS
#304Solid ganaxolone compositions and methods for the making and use thereof
#305Pharmaceutical composition
#306GRAS Enteric Coating Formulations and Methods of Making and Using Same
#307Controlled release hydrocodone formulations
#308PHARMACEUTICAL COMPOSITIONS
#309Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection
#310Bilayer tablet formulations
#311Liquid ganaxolone formulations and methods for the making and use thereof
#312ABUSE-RESISTANT OPIOID DOSAGE FORM
#313Composition comprising shellac and/or a salt thereof and sodium starch glycolate
#314Delayed release tablet with defined core geometry
#315Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone
#316FOOD AND FLAVORANT COMPOSITIONS COMPRISING RENEWABLY-BASED, BIODEGRADABLE 1,3-PROPANEDIOL
#317CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITION
#318Controlled release and taste masking oral pharmaceutical composition
#319Pulsatile drug release
#320Dosage forms of bisphosphonates
#321Oral antimicrobial pharmaceutical compositions
#322Direct Compression Polymer Tablet Core
#323Pharmaceutical composition
#324DIRECT COMPRESSION POLYMER TABLET CORE
#325Controlled Release and Taste Masking Oral Pharmaceutical Composition
#326ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS
#327Oral antimicrobial pharmaceutical compositions
#328Controlled release and taste making oral pharmaceutical composition
#329Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
#330Methods for the Treatment of CNS-Related Conditions
#331ORGANIC COMPOUNDS
#332Bilayer tablet formulations
#333Methods for the treatment of CNS-related conditions
#334Compositions for the treatment of CNS-related conditions
#335Pharmaceutical Composition and Administrations Thereof
#336ABUSE-RESISTANT OPIOID DOSAGE FORM
#337Coated Tablets, Their Method of Preparation, and Related Uses
#338ABUSE-RESISTANT OPIOID DOSAGE FORM
#339PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF
#340Controlled Release and Taste Masking Oral Pharmaceutical Composition
#341Tablets with Site- and Time- Controlled Gastrointestinal Release of Active Ingredient
#342Controlled release and taste masking oral pharmaceutical composition
#343Oral antimicrobial pharmaceutical compositions
#344Coated solid dosage forms
#345Beta 2 adrenergic receptor agonists such as terbutaline for use in the treatment of nocturnal hypoglycemia
#346Composition Comprising S-Allyl-L-Cysteine as Active Ingredient for Preventing or Treating Gastrointestinal Disorders
#347PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE
#348Delayed release tablet with defined core geometry
#349Delayed release tablet with defined core geometry
#350TESTOSTERONE UNDECANOATE COMPOSITIONS
#351PHARMACEUTICAL COMPOSITIONS
#352DOSAGE FORMS OF RISEDRONATE
#353COMPOSITION COMPRISING AN ANIONIC POLYMERIC MATERIAL AND THE SALT OF A SATURATED MONOCARBOXYLIC ACID HAVING 6 TO 22 CARBON ATOMS
#354Detergent composition containing bio-derived 1,3-propanediol and its conjugate esters
#355Liquid ganaxolone formulations and methods for the making and use thereof
#356METHOD OF TREATING INSOMNIA
#357CONTROLLED RELEASE AND TASTE-MASKING ORAL PHARMACEUTICAL COMPOSITION
#358Controlled release and taste masking oral pharmaceutical composition
#359ACTIVE COATING OF PHARMACEUTICAL DOSAGE FORMS
#360Solid Dosage Forms Of Bendamustine
#361Bioactive Dose Having a Rapid Release Coating or Rapid Release Layer Containing a Material for Modulating pH of a Bodily Fluid to Help or Hinder Absorption of a Bioactive
#362Dissolution stability of calcium carbonate tablets
#363Film coating composition and methods of making and using the same
#364Coating composition and use thereof
#365SHELLAC ENTERIC COATINGS
#366Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
#367Controlled release hydrocodone formulations
#368Film-coated scored tablet
#369Solid ganaxolone formulations and methods for the making and use thereof
#370DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
#371Controlled release metformin formulations
#372Smooth, high solids tablet coating composition
#373ABUSE-RESISTANT OPIOID DOSAGE FORM
#374Carbidopa/Levodopa gastroretentive drug delivery
#375PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE
#376Methods and compositions for the treatment of CNS-related conditions
#377PHARMACEUTICAL COMPOSITIONS
#378STABLE BENZIMIDAZOLE FORMULATION
#379ABUSE-RESISTANT OPIOID DOSAGE FORM
#380NOVEL DOSAGE FORM
#381Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing
#382Oral Formulations for 5-HT-Receptor Agonists, Uses and Methods of Treatment Employing The Same
#383Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
#384Methods and compositions for the treatment of CNS-related conditions
#385SOLID PHARMACEUTICAL COMPOSITION COMPRISING 1-(4-CHLOROANILINO)-4-(4-PYRIDYLMETHYL)PHTHALAZINE AND A PH MODIFIER
#386PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF
#387Personal care composition containing bio-derived 1,3-propanediol and its conjugate esters
#388Oral preparation comprising specific organic acid, and method for improvement in elution property and chemical stability of oral preparation
#389Enteric coated, soluble creatine and polyethylene glycol composition for enhanced skeletal uptake of oral creatine
#390Enteric coated, soluble creatine and polyethylene glycol composition for enhanced skeletal uptake of oral creatine
#391Stable pharmaceutical composition comprising a hydrosoluble vinflunine salt
#392DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF RHEUMATOID ARTHRITIS BY IMPROVING SIGNS AND SYMPTOMS, SHOWING MAJOR OR COMPLETE CLINICAL RESPONSE AND BY PREVENTING FROM JOINT DAMAGE
#393DOSAGE FORMS OF RISEDRONATE
#394Low dosage forms of risedronate or its salts
#395Low dosage forms of risedronate or its salts
#396Immediate release dosage forms of sodium oxybate
#397Dosage forms of bisphosphonates
#398Pharmaceutical composition and administration thereof
#399PROCESS FOR PRODUCTION OF TABLET
#400RELEASE OF STATINS IN THE INTESTINE
#401CHITOSAN SOLUTION AND MEDICAL PREPARATION WITH CHITOSAN COATING FORMED FROM THE SOLUTION
#402ORGANIC COMPOUNDS
#403Personal care and cosmetics compositions comprising biologically-based mono and di esters
#404Dried and/or microencapsulated cells with a high content of (s)-(+)-s-adenosyl-l-methionine, process for their preparation, and compositons containing said cells
#405PHARMACEUTICAL COMPOSITIONS FOR THE ORAL OR RECTAL ADMINISTRATION OF PROTEIN SUBSTANCES
#406ENTERIC COATED HYDROPHOBIC MATRIX FORMULATION
#407DETERGENT AND LIQUID SOAP COMPOSITIONS COMPRISING BIOLOGICALLY-BASED MONO AND DI ESTERS
#408COMPOSITION FOR ORAL USE BASED ON S-ADENOSYLMETHIONINE AND A PROCESS FOR THEIR PREPARATION
#409Dry Coating using Twin-Screw Kneader
#410Dosage form time-lagged of drugs for the therapy of insomnia
#411Direct compression polymer tablet core
#412Method of measuring coating quantity and method of predicting dissolution behavior
#413FORMULATIONS FOR POORLY PERMEABLE ACTIVE PHARMACEUTICAL INGREDIENTS
#414Water dispersible enteric coating formulation of nutraceutical and pharmaceutical dosage forms
#415Controlled release delivery device comprising an organosol coat
#416Deicing and anti-icing compositions comprising renewably-based, biodegradable 1,3-propanediol
#417Pharmaceutical composition
#418Oral compositions containing a salivation inducing agent
#419Misuse preventative, controlled release formulation
#420Gabapentin-containing solid compositions and process for preparing the same
#421Method of manufacturing modified release dosage forms
#422Pharmaceutical compositions
#423Alcohol Resistant Pharmaceutical Formulations
#424Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
#425PHARMACEUTICAL COMPOSITIONS OF SIROLIMUS
#426SOLID ORAL COMPOSITIONS BASED ON S-ADENOSYL METHIONINE AND/OR NADH AND PROCESS FOR OBTAINING THEM
#427SIROLIMUS HAVING SPECIFIC PARTICLE SIZE AND PHARMACEUTICAL COMPOSITIONS THEREOF
#428Pulsatile gastric retentive dosage forms
#429COATED TABLETS, THEIR METHODS OF PREPARATION, AND RELATED USES
#430Controlled release and taste masking oral pharmaceutical composition
#431ENTERIC COATED, SOLUBLE CREATINE AND POLYETHYLENE GLYCOL COMPOSITION FOR ENHANCED SKELETAL UPTAKE OF ORAL CREATINE
#432Polymer Composition And Dosage Forms Comprising The Same
#433Direct compression polymer tablet core
#434Low Dosage Forms Of Risedronate Or Its Salts
#435Low Dosage Forms Of Risedronate Or Its Salts
#436Controlled release composition
#437ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS
#438Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel process for preparing other forms
#439Aqueous Pharmaceutical Coating
#440PHARMACEUTICAL METHODS, DOSING REGIMES AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
#441LOW-DOSAGE PERORAL MEDICATION FOR CONTRACEPTION CONTAINING CRYSTALLINE DIENOGEST AND ETHINYL ESTRADIOL
#442SOLID ORAL DOSAGE VITAMIN AND MINERAL COMPOSITIONS
#443Pharmaceutical Methods, Dosing Regimes And Dosage Forms For The Treatment Of Alzheimer's Disease
#444Novel Extended Release Composition of Venlafaxine Hydrochloride Containing Polyvinyl Acetate
#445Osmotic drug delivery system
#446Oral antimicrobial pharmaceutical compositions
#447Biodegradable compositions comprising renewably-based, biodegradable 1,3-propanediol
#448Pharmaceutical Methods, Dosing Regimes And Dosage Forms For The Treatment Of Alzheimer's Disease
#449Pharmaceutical Methods, Dosing Regimes And Dosage Forms For The Treatment Of Alzheimer's Disease
#450NON-HOMOGENOUS DOSAGE FORM COATINGS
#451Controlled Release Pharmaceutical Formulation
#452Detergent and liquid soap compositions comprising biologically-based mono and di esters
#453Detergent compositions comprising renewably-based, biodegradable 1,3-propanediol
#454Compositions comprising mono and di esters of biologically-based 1,3-propanediol
#455Personal care and cosmetic compositions comprising renewably-based, biodegradable 1,3-propanediol
#456Food compositions comprising biologically-based biodegradable 1,3-propanediol esters
#457Plasticizers comprising biologically-based mono and di esters
#458Synthesis of mono and di esters from biologically-produced 1,3-propanediol
#459Bio-derived 1,3-propanediol and its conjugate esters as natural and non irritating solvents for biomass-derived extracts, fragrance concentrates, and oils
#460Personal care and cosmetics compositions comprising biologically-based mono and di esters
#461Natural deodorant compositions comprising renewably-based, biodegradable 1,3-propanediol
#462Heat transfer compositions comprising renewably-based biodegradable 1,3-propanediol
#463Deicing and anti-icing compositions comprising renewably-based, biodegradable 1,3-propanediol
#464Coating process to produce controlled release coatings
#465Modified release formulations of tramadol and uses thereof
#466Compositions for oral use based on S-adenosylmethionine and a process for their preparation
#467Controlled release metformin formulations
#468Solid ganaxolone formulations and methods for the making and use thereof
#469Liquid ganaxolone formulations and methods for the making and use thereof
#470Coated diclofenac tablets
#471Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing
#472Delayed release tablet with defined core geometry
#473Gastro-resistant and ethanol-resistant controlled-release formulations comprising hydromorphone
#474Adhesives and their applications
#475Oral compositions containing a salivation inducing agent
#476Oral formulation for 5-ht-receptor agonists, uses and methods of treatment employing the same
#477Formulation for providing an enteric coating material
#478Controlled delivery creatine formulations and method of using the same
#479Coated tablets
#480Methods and compositions for the treatment of CNS-related conditions
#481SYSTEMS, METHODS AND APPARATUSES FOR MANUFACTURING DOSAGE FORMS
#482Taste masked sumatriptan tablets and processes for their preparation
#483Sustained-release oral administration preparation of phenylalanine derivatives
#484Method for producing a controlled release preparation
#485Controlled release and taste masking oral pharmaceutical composition
#486Controlled release and taste masking oral pharmaceutical composition
#487Light-blocking agent and film-forming composition
#488Dosage forms of risedronate
#489Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
#490Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
#491Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
#492Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
#493Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
#494Aqueous shellac coating agent and production process therefor, and coated food and production process therefor, coated drug and production process therefor, glazing composition for oil-based confectionary, glazing process, and glazed oil-based confectionary using same
#495Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
#496Tablets with site- and time-controlled gastrointestinal release of active ingredient
#4974-phenylbutyric acid controlled-release formulations for therapeutic use
#498Direct compression polymer tablet core
#499Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
#500Processes for preparing amorphous atorvastatin hemi-calcium
#501Modified release dosage forms
#502Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
#503Processes for preparing amorphous atorvastatin hemi-calcium
#504Processes for preparing amorphous atorvastatin hemi-calcium
#505Dosage forms of bisphosphonates
#506Direct compression polymer tablet core
#507Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
#508Modified-release compositions of at least one form of venlafaxine
#509Enteric coatings for orally ingestible substrates
#510Gastroprotected formulations containing alph-amylase inhibitors
#511Systems, methods and apparatuses for manufacturing dosage forms
#512Systems, methods and apparatuses for manufacturing dosage forms
#513Method and apparatus for transferring substrates
#514Analgesics
#515Edible PGA coating composition
#516Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
#517Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
#518Controlled release composition with semi-permeable membrane and poloxamer flux enhancer
#519Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
#520Composite dosage forms
#521Controlled release composition
#522Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
#523Pharmaceutical coating composition and method of use
#524Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the same
#525Release stable mesalamine dosage forms